Molecular structure
Mechanism of action
Retatrutide is a novel triple-agonist research peptide targeting GLP-1, GIP, and glucagon receptors. Third-party tested for purity (>=98%) by Janoshik Analytical.
Research applications
This compound is supplied exclusively for in vitro and ex vivo research applications. Researchers are responsible for compliance with all applicable institutional, local, and national regulations governing the use of investigational compounds.
References
- [1]Third-party analytical test report available via COA download above.
- [2]Refer to primary literature for mechanism of action and pharmacokinetic data.
- [3]ClinicalTrials.gov — search compound name for registered studies.
- [4]PubMed — peer-reviewed publications indexed under compound name and CAS number.
Unit price
$329.00
Per 10mg vial
Research use only. This product is intended for laboratory research purposes only. Not for human consumption. Not a drug, food supplement, or cosmetic. Not evaluated by Health Canada or the FDA for therapeutic use. Misuse of research compounds may be illegal. The purchaser assumes full responsibility for compliance with all applicable regulations.
Related compounds
Tirzepatide 30mg
30mg vial
Dual GLP-1 / GIP agonist for metabolic research.
Semaglutide 10mg
10mg vial
GLP-1 receptor agonist for metabolic research.
Tesamorelin 10mg
10mg vial
Growth hormone-releasing factor analog for visceral fat research.
MOTS-c 10mg
10mg vial
Mitochondrial-derived peptide for metabolic research.